Premium
HMG‐CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus
Author(s) -
Nakashima A.,
Nakashima R.,
Ito T.,
Masaki T.,
Yorioka N.
Publication year - 2004
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2004.01292.x
Subject(s) - medicine , endocrinology , diabetes mellitus , bone mineral , hmg coa reductase , body mass index , reductase , excretion , type 2 diabetes mellitus , alkaline phosphatase , enzyme , osteoporosis , biochemistry , chemistry
Aims It has been reported that 3‐hydroxy‐3‐methylglutaryl co‐enzyme A (HMG‐CoA) reductase inhibitors increase bone mineral density (BMD) in vivo . We investigated the effect of HMG‐CoA reductase inhibitors on BMD in patients with Type 2 diabetes mellitus. Patients and methods We selected 122 patients with Type 2 diabetes, who were not taking active vitamin D preparations. Their mean age was 67.3 ± 9.2 years. They were divided into a control group ( n = 63) without HMG‐CoA reductase inhibitor therapy and an HMG‐CoA group ( n = 59) who were treated with these drugs. The BMD of the distal one‐third of the radius was measured by dual‐energy X‐ray adsorptiometry at baseline and after 2 years. Results There were no significant differences between the control and HMG‐CoA groups at baseline with respect to age, gender, body mass index, duration of diabetes, haemoglobin A 1c , fasting plasma glucose, adjusted calcium, serum phosphorus, alkaline phosphatase, albumin excretion rate and radial BMD. However, there was a significantly smaller annual decrease of the radial BMD in the HMG‐CoA group. Multiple regression analysis with a forward elimination procedure revealed a positive correlation of the radial BMD Z‐score with body mass index, while there was a negative correlation with alkaline phosphatase and albumin excretion rate. In addition, the annual rate of change of the radial BMD showed a positive correlation with HMG‐CoA reductase inhibitor therapy. Conclusions These findings suggest that HMG‐CoA reductase inhibitors may prevent bone loss in patients with Type 2 diabetes.